Kornimate/medical-research-clean huggingface dataset:
mandala art and value clarification with parents of children with cancer

Conditions: Nursing Caries

Summary: the research is planned to be conducted with a randomized controlled experimental study. in the research, it is aimed to determine the effect of mandala drawing art and value clarification application based on watson human care theory on the anxiety and mood of the parents of children with cancer.

the population of the study consists of the parents of children diagnosed with cancer in the akdeniz university hospital pediatric hematology and oncology clinic. the sample of the study is three groups; intervention 1 group (n:25), intervention 2 group (n:25) and control group (n:25) will consist of a total of 75 parents. a closed envelope system with simple randomization will be used in sample selection. intervention 1 group will participate in 2 sessions of individual mandala drawing art activity with the theme of 'emotions' accompanied by classical or instrumental music. in each session, a mandala will be created. intervention 2 groups will participate in the value clarification activity by writing 2 sessions individually with the theme of 'emotions' accompanied by classical or instrumental music. personal information form, state anxiety inventory and positive-negative affect scale were administered to the intervention groups at the first meeting in order to collect pre-test data. to collect post-test data, the state anxiety inventory and the positive-negative affect scale were administered immediately after the second session. no intervention will be made to the control group, the same data collection tools were applied to the intervention groups. in addition, iin the second session, the parent was asked to interpret the colors and shapes in the mandala created by the parent and a face-to-face interview was held.

Eligibility criteria:
inclusion criteria: * having the ability to read, write, speak and understand turkish * being the parent of a 0-17-year-old child diagnosed with cancer * staying in the hospital with child * being hospitalized for at least the second course of treatment of the child exclusion criteria: * having a physical problem that may prevent you from drawing and typing a mandala and participating in value clarification * not being able to take a break from caring for their child and participate in individual activities * having the child in the terminal period * relapse disease of the child

Keywords: child value clarification parent cancer mandala art therapy
efficacy and safety study of binodenoson in assessing cardiac ischemia

Conditions: Coronary Artery Disease

Summary: binodenoson (an experimental drug) and adenosine (an fda-approved drug that is currently used by doctors) are used to increase blood flow to the heart just like when a person exercises on a treadmill. using imaging techniques, this increased blood flow can help determine if areas of the heart are not getting enough blood and oxygen during exercise. the purpose of the study is to determine if binodenoson is as good as adenosine in determining if there are areas of the heart not getting enough oxygen when blood flow to the heart is increased.


Eligibility criteria:
inclusion criteria: * able to understand and sign an informed consent form. exclusion criteria: * women who are of childbearing potential. * very low likelihood of coronary artery disease (by american heart association and american college of cardiology standards). * documented history of acute myocardial infarction within 30 days. * percutaneous coronary intervention or coronary bypass graft surgery within 3 years, unless typical or atypical anginal symptoms are present. * reactive airway disease or other contraindication that preclude a patient from receiving adenosine. * previous heart transplant or listed to receive a heart transplant. * cardiomyopathy (idiopathic dilated, restrictive, hypertrophic). * history of hemodynamically significant supraventricular tachycardia or sustained ventricular tachycardia. * presence of second- or third-degree av block (in the absence of permanent pacemaker). * left ventricular ejection fraction greater than 35%, known prior to the first imaging procedure. * presence of advanced heart failure, new york heart association class iv. * history of vasospastic/prinzmetal angina. * active (under treatment) cancer (except skin cancers). * inability to discontinue antianginal medications, aggrenox®, dipyridamole, and xanthine-containing drugs and foods (including caffeine) as required prior to each imaging procedure. * previous participation in a study of binodenoson. * any physical or psychosocial condition that, based on the investigator's judgment, would prevent the patient from completing the study.

Keywords: coronary artery disease angina anginal symptoms ischemic heart disease ischemia single photon emission computed tomography pharmacologic stress myocardial perfusion imaging suspected coronary artery disease known coronary artery disease typical or atypical anginal symptoms
effect of perineal massage combined with cold compress in the second stage on the delivery outcome of primipara

Conditions: Cold Compress

Summary: objective: the aim of this study was to investigate the effect of perineal massage and cold compress in second stage on the delivery outcome of primipara. method: this interventional study included a total of 200 primipara hoping for natural birth. patients were randomly divided into two groups, one group used routine labor, one group used cold compress and perineal massage. record the time of second stage of labor, degree of perineal laceration, etc.


Eligibility criteria:
inclusion criteria: * want give birth naturally * have well developed perineum exclusion criteria: * abnormal fetal position and head basin * severe obstetric complications

Keywords: the second labor perineal laceration perineal massage
feasibility of lactate level evaluation in prehospital care in trauma

Conditions: Trauma, Multiple; Lactate Blood Increase

Summary: capillary or venous lactate level evaluation in prehospital care could be simple and beneficial tool for optimising prehospital care in patients with severe trauma.

evaluation of blood lactate level and its trend are important morbidity and mortality predictive factors. in prehospital care, lactate level is more sensitive marker and have better prognostic value in severe trauma than basic vital signs. worse outcome is associated with levels between 2 - 4 mmol/l. measurement of lactate level in venous or capillary blood is quick and simple method with minimal risks and with no special needs for medical staff training. in spite of good availability of this method in the czech republic the method feasibility has never been analysed in patients with severe trauma.

Eligibility criteria:
inclusion criteria: * patient having / suspected to have severe trauma treated by cooperating emergency medical system organization exclusion criteria: * possible alterations of plasma lactate level in the time of trauma (seizure, malignity, use of beta-2 agonists, severe liver and/or kidney failure, ketoacidosis, intoxication)
efficiency of the king vision video laryngoscope

Conditions: Respiratory Failure; Intubation

Summary: the investigators studied the efficiency of macintosh laryngoscope and the king vision video laryngoscope in adult patients scheduled for general anesthesia. best cormack-lehane score obtained, glottic view time, intubation time, time to ventilation, correlation between the mallampati classification and the cormack-lehane grades, and complications related to laryngoscopy and intubation has been investigated.

securing the airway is essential in general anesthesia. anesthetic problems related to airway management constitute 17% of closed claims, difficult intubation being the most common one with an occurrence rate of 5%. problems like delayed intubation, misplaced tracheal tube, or airway trauma are frequently seen in outpatient settings and end up with either death or hypoxic brain damage. therefore, preoperative visit should include detailed assessment of the airways according to clues of difficult intubation.several studies compared the king vision video laryngoscope with other laryngoscopes in manikins simulating difficult airway scenarios, and reported better glottic views. the investigators aimed to study the correlation between the mallampati classification and the glottic views (cormack-lehane grade) obtained with macintosh laryngoscopy, and the king vision video laryngoscopy in adult patients scheduled for general anesthesia. secondary outcomes will be successful intubation rate, time to obtain the best view, time to successful intubation, and complications related to laryngoscopy will be compared.

Eligibility criteria:
inclusion criteria: * scheduled for general anesthesia * age higher than 18 years * age lower than 60 years exclusion criteria: * emergency surgery * mouth opening less than 2 cm * american society of anesthesiologists (asa) score higher than 2 * oropharyngeal anomaly * glottic or supraglottic mass * history of surgery due to oropharyngeal anomaly, glottic or supraglottic mass
study of gastroduodenal metallic stent vs gastrojejunostomy

Conditions: Gastric Cancer

Summary: selection of the optimal treatment for gastric outlet obstruction in patients with radically unresectable gastric cancer remains controversial because previous studies comparing the two procedures had a small sample size as well as they included various etiologies such as gastrointestinal (gi) cancer, duodenal cancer and pancreaticobiliary cancer in selecting the patient population. therefore, to establish the standard of care for patients with radically unresectable gastric cancer with gastric outlet obstruction, a larger prospective, randomized, controlled clinical trial using a single type of stent is warranted.


Eligibility criteria:
inclusion criteria: * patients aged ≥19 to 80 years * ecog performance status 0-3 * life expectancy \>3 months * patients with malignant gastric outlet obstruction (distal part of stomach, pyloric ring or duodenal bulb obstruction) caused by gastric cancer * patients who are not eligible for radical operation due to local progression of gastric cancer, distant metastasis or his/her general condition. * patients with gooss score 0-2 * patients with symptoms consistent with gastric outlet obstruction including persistent nausea and vomiting * patients with findings consistent with malignant gastric outlet obstruction on imaging studies including upper gi endoscopy, upper giseries or abdominal computed tomography (ct) * patients who are eligible to undergo both gastroduodenal stent placement and gastrojejunostomy (eligibility will be determined by agreement by at least one gastroenterological surgeon and at least one radiologist) * patients who have been provided with an explanation of the procedures of the clinical trial, voluntarily decided participation and signed the informed consent form exclusion criteria: * pregnant or lactating women * women of childbearing potential with positive pregnancy test at baseline. post-menopausal women should have at least 12 months of amenorrhea to be considered not of childbearing potential. * patients who have previously undergone balloon dilatation or stent placement for malignant gastric outlet obstruction * patients with past history of palliative bypass surgery or gastrectomy * patients with peritoneal metastasis or multiple intestinal obstruction caused by other cause on imaging scan including abdominal ct or small bowel series * patients who have been treated for intestinal adhesion caused by previous abdominal surgery * patients who are not eligible for general anesthesia due to poor general condition * patients with clinical evidence of intestinal perforation or peritonitis * patients who are determined to be not eligible for stent placement or gastrojejunostomy due to other cause
lotus: global acute stroke study utilizing penumbra system

Conditions: Stroke, Ischemic

Summary: the primary objective of this study is to demonstrate safety and effectiveness of the penumbra system in a population with acute ischemic stroke (ais) secondary to intracranial large vessel occlusion (lvo).


Eligibility criteria:
inclusion criteria: * patient age ≥ 18 and ≤ 85 * patient experiencing acute ischemic stroke secondary to intracranial large vessel occlusion who are eligible for mechanical thrombectomy using the penumbra system * planned frontline treatment with aspiration utilizing penumbra system * present with symptoms consistent with an acute ischemic stroke within 8 hours of stroke symptom onset * national institute of health stroke scale (nihss) ≥ 6 * signed informed consent per institution review board/ethics committee * ct aspect score from 6 to 10 (≥ 6) or according to mr dwi aspect score from 5 to 10 (≥ 5) * pre-stroke mrs 0-1 exclusion criteria: * any comorbid disease or condition expected to compromise survival or ability to complete follow-up assessments through 90 days * associated myocardial infarction or severe infection (endocarditis or sepsis) * laboratory evidence of coagulation abnormalities, with an international normalized ratio (inr) or \> 3.0 or platelets count \ 50 sec * uncontrolled hypertension (defined as systolic blood pressure \> 185 mmhg or diastolic blood pressure \> 110 mmhg) * baseline glucose \ 22.2 mmol/l * seizure at the onset of stroke * time of stroke symptom onset unknown * females who are pregnant * known serious sensitivity to radiographic contrast media that cannot be pre-treated * renal failure as defined by serum creatinine \> 3.0mg/dl (264 µmol/l) * currently participating in an investigational (drug, device, etc.) clinical trial that will confound study endpoints. patients in observational, natural history, and/or epidemiological studies not involving intervention are eligible * ct/mri evidence of the following conditions at screening: significant mass effect with midline shift, evidence of intracranial hemorrhage (ich), aneurysm, or arteriovenous malformation (avm), or intracranial tumor * . angiographic evidence of preexisting arterial injury, such as carotid dissection, complete cervical carotid occlusion, or vasculitis. * angiographic evidence of occlusions in multiple vascular territories (e.g., bilateral anterior circulation, or anterior circulation/vertebrobasilar system) as confirmed on cta/mra, or clinical evidence of bilateral strokes or strokes in multiple territories * excessive arterial tortuosity that would prevent the device from reaching the target vessel

Keywords: large vessel occlusion lvo mechanical thrombectomy penumbra system
storage temperature and quality of leucoreduced whole blood

Conditions: Trauma; Austere Environment; Blood Bank; Buddy Transfusion

Summary: in a combat situation the need for safe and high-quality blood products is increasing. wb (whole blood) is used in many trauma situations, but we wish to investigate whether there is an even better whole blood product. the purpose of this study is to examine the quality of leucoreduced, cold-stored whole blood. we also wish to examine the effects of filtration of whole blood without a 1-2 hour holding-time (warm-filtration) and the effects of forced filtration. we also wish to explore the possibility of using cold-stored wb for production of rcc. analyses are performed with a main focus to investigate function and quality of red blood cells and platelets.


Eligibility criteria:
inclusion criteria: * healthy volunteer * age between 18 and 70 * negative pregnancy test (women in fertile age) * blood pressure range: (160-100)/(100-40) * pulse range: 40-100 exclusion criteria: * usage of platelet-influencing medication * mild flu or more severe illnesses * open wound * pregnancy or trying to get pregnant

Keywords: blood whole blood cold-storage filtration transfusion platelet-function
regimen of alfentanil in propofol sedative fibro-bronchoscopy

Conditions: Hypoxemia

Summary: alfentanil (alf) is used in combination with propofol (pro) in fiber-bronchoscopy and in many other conscious sedation procedures. alf and pro have the characteristic of rapid anesthetic onset and quick recovery, synergic sedative effect and unwanted side effects too. however, the amount of alf needed in combination with pro for induction and the timing of administration was no standardized. the investigators designed this study to evaluate the optimal regimen, dose and timing of alf in target-controlled infusion (tci) of pro for flexible bronchoscopy sedation, and also to evaluate the influence of variable regimen of alf and pro on hypoxemia, hypotension, cough severity, and pro injection related pain.

alfentanil (alf) is used in combination with propofol (pro) in fiber-bronchoscopy and in many other conscious sedation procedures. alf and pro have the characteristic of rapid anesthetic onset and quick recovery, synergic sedative effect and unwanted side effects too. however, the amount of alf needed in combination with pro for induction and the timing of administration was no standardized. the investigators designed this study to evaluate the optimal regimen, dose and timing of alf in target-controlled infusion (tci) of pro for flexible bronchoscopy sedation. method: patients will be enrolled and assigned randomly into five groups. in group 1, normal saline two minutes before and alf 2.5μg/kg before pro were given; in group 2, normal saline two minutes before and alf 5μg/kg before pro were given; in group 3, alf 2.5μg/kg two minutes before and normal saline before pro were given; in group 4: alf 5μg/kg two minutes before and normal saline before pro were given; in group 5, normal saline two minutes and before pro were given. concentration of effect site to loss of consciousness (loc), dose of pro to loc, and induction time of variable regimen, as well as hypoxemia, hypotension, cough severity, and pro injection related pain will be recorded and analyzed.

Eligibility criteria:
inclusion criteria: * patients who required elective sedative bronchoscopy exclusion criteria: * any physical, psychiatric, social problem that avoid from conscious level evaluation, * hypersensitivity or allergy to propofol, alfentanil * severe chronic obstructive pulmonary disease (forced expiratory volume in 1 s ,50% of predicted value, or requirement for oxygen therapy) * unstable haemodynamic status (defined as a heart rate \< 60 or ≧ 120 bpm and/or * a systolic blood pressure (sbp) \< 100 or ≧ 180 mmhg) * predictable difficult upper airways (mallampati classification score of iv) * severe obstructive sleep apnea with apnea hypopnea index (ahi) \> 45 * body mass index (bmi) more than 42 in male and 35 in female * renal insufficiency * liver cirrhosis

Keywords: sedative bronchoscope alfentanil doses propofol targeted controlled infusion hypoxemia
an assistant model for ird care needs: a randomized control trial

Conditions: Inherited Retinal Diseases

Summary: conduct a multicenter randomized controlled study based on the comprehensive deep learning model for inherited retinal diseases (eyefm-irds). through our established comprehensive deep learning model for inherited retinal diseases (eyefm-irds model), the following objectives can be achieved: complete the initial screening of ird patients based on the eyefm-irds model, improve the correct referral of ird patients to the fundus specialty or genetic eye disease specialty clinic; through consultation and ophthalmic examination, achieve the goal that the eyefm-irds assisted by fundus doctors can improve the diagnosis of ird compared to fundus doctors alone, effectively screen out negative patients, and avoid unnecessary wes examinations; based on a panel of gene mutation types with treatment methods that we have previously constructed. the eyefm-irds model predicts the specific mutation genes of ird patients based on consultation and fundus examination. this will improve the standardized diagnosis and treatment of ird diseases, and also provide clinical support and research guidance for future research on irds.


Eligibility criteria:
inclusion criteria: * presenting with clinical features suggestive of ird based on the initial assessment by the physician exclusion criteria: * refusal to undergo wes genetic testing. * screening for a history of intraocular surgery in both eyes within the past 6 months; * subjects with severe systemic diseases, intellectual developmental disorders, psychiatric illnesses, etc. * patient data that the investigator deems necessary to exclude.
efficacy and safety study of durvalumab maintenance in patients with stage iii non-small cell lung cancer

Conditions: Bronchial Cancer

Summary: the aim of this study is to evaluate the real-life efficacy of durvalumab treatment in consolidation after radio-chemotherapy.

immune checkpoint inhibitors (icis) such as anti-pd-1/pd-l1 have revolutionized the field of immuno-oncology, inducing significant and durable responses in patients with all types of tumor, and in particular advanced stage (ii-iv) non-small cell lung cancer (nsclc). the use of durvalumab in consolidation, after radiochemotherapy, in locally advanced nsclc has significantly improved progression-free survival and overall survival (see pacific trial). durvalumab now has marketing authorization for this indication, in cases of pd-l1≥1% overexpression on tumor cells. however, 50% of patients experience tumor progression at 1 year, and there is currently no biomarker (clinical, biological or radiological) predictive of tumor response to durvalumab in consolidation. elucidating the determinants of response and resistance to treatment, as well as predicting severe immune-mediated adverse events, are essential to improving patient outcomes and developing new therapeutic strategies translated with deepl.com (free version)

Eligibility criteria:
inclusion criteria: * patients with unresectable locally advanced non-small-cell lung cancer (stages ii, iiia, iiib and iiic) responding to or stable after concomitant or sequential platinum-based radiochemotherapy and having received durvalumab consolidation therapy * minimum radiotherapy dose of 54 gy to 66 gy * age greater than or equal to 18 years * who 0-1 * non-opposition of living patients formulated exclusion criteria: * age \< 18 years. * refusal to participate * patients under legal protection (curatorship, guardianship, etc.)
molecular profiling and dynamic changes of ctdna in unresectable locally advanced nsclc

Conditions: Lung Cancer; Stage III Lung Cancer; Unresectable Lung Carcinoma

Summary: multi-center observational clinical study to evaluate the application value of ctdna monitoring in efficacy assessment and relapse prediction in patients diagnosed with unresectable, locally advanced nsclc receiving crt with or without durvalumab maintenance treatment.

newly diagnosed, histologically confirmed, unresectable stage iii nsclc patients, amenable to receive standard of care chemoradiotherapy with or without durvalumab maintenance, will be enrolled in this study. whole blood collection will be conducted during the treatment for ctdna detection in specific time-points of interest. next-generation sequencing using commercially available panels, and analysis of ctdna aberrant methylation will be performed. results will be correlated to patients' recurrence times and survival outcomes.

Eligibility criteria:
inclusion criteria: * patients with newly diagnosed, histologically confirmed, unresectable locally advanced nsclc. * ≥18 years of age. * ability to understand the written informed consent and willingness to sign it. exclusion criteria: * patients who are unwilling to follow-up evaluation of response to therapy. * any condition that, in the opinion of the investigator, would interfere with study results.

Keywords: liquid biopsy ctdna chemoradiotherapy